AbbVie Inc. $ABBV Stock: Private Advisor Group LLC Boosts Holdings

Private Advisor Group LLC raised its position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 32.3% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 308,622 shares of the company’s stock after purchasing an additional 75,408 shares during the quarter. Private Advisor Group LLC’s holdings in AbbVie were worth $80,732,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. Hartford Funds Management Co LLC bought a new stake in AbbVie during the 3rd quarter worth approximately $349,000. Ieq Capital LLC lifted its holdings in AbbVie by 36.0% during the 3rd quarter. Ieq Capital LLC now owns 138,821 shares of the company’s stock worth $36,314,000 after buying an additional 36,740 shares in the last quarter. Focus Advisor Solutions LLC boosted its holdings in AbbVie by 62.8% in the third quarter. Focus Advisor Solutions LLC now owns 64,299 shares of the company’s stock valued at $16,820,000 after acquiring an additional 24,814 shares during the last quarter. Colonial Trust Co SC raised its stake in shares of AbbVie by 0.9% during the third quarter. Colonial Trust Co SC now owns 7,891 shares of the company’s stock worth $2,064,000 after buying an additional 74 shares during the last quarter. Finally, Checchi Capital Advisers LLC lifted its stake in shares of AbbVie by 0.7% in the 3rd quarter. Checchi Capital Advisers LLC now owns 20,075 shares of the company’s stock valued at $5,251,000 after purchasing an additional 135 shares during the period. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Stock Performance

ABBV stock opened at $285.92 on Thursday. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $302.93. The company has a market capitalization of $505.39 billion, a PE ratio of 49.21, a price-to-earnings-growth ratio of 1.33 and a beta of 0.20. The company’s 50-day simple moving average is $277.84 and its 200 day simple moving average is $241.96.

AbbVie (NYSE:ABBV – Get Free Report) last posted its quarterly earnings data on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.73 by $0.09. The firm had revenue of $17.40 billion during the quarter, compared to the consensus estimate of $17.32 billion. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.86 EPS. On average, analysts forecast that AbbVie Inc. will post 13.98 EPS for the current year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 16th. Shareholders of record on Friday, January 15th will be paid a dividend of $1.82 per share. The ex-dividend date is Friday, January 15th. This is a positive change from AbbVie’s previous quarterly dividend of $1.73. This represents a $7.28 dividend on an annualized basis and a yield of 2.5%. AbbVie’s dividend payout ratio is currently 119.10%.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on ABBV. BNP Paribas Exane boosted their target price on AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 11th. Argus upped their target price on shares of AbbVie from $250.00 to $270.00 in a research note on Tuesday, August 4th. Barclays lifted their target price on AbbVie from $325.00 to $335.00 and gave the company an “overweight” rating in a research report on Monday. Cantor Fitzgerald increased their price objective on shares of AbbVie from $290.00 to $325.00 and gave the stock an “overweight” rating in a research note on Monday, November 2nd. Finally, Wells Fargo & Company raised their target price on shares of AbbVie from $300.00 to $340.00 and gave the company an “overweight” rating in a research note on Monday, November 2nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $299.62.

Check Out Our Latest Report on ABBV

Insider Transactions at AbbVie

In related news, EVP Jeffrey Stewart sold 40,619 shares of AbbVie stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $293.60, for a total value of $11,925,738.40. Following the transaction, the executive vice president directly owned 83,171 shares of the company’s stock, valued at $24,419,005.60. This trade represents a 32.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.06% of the stock is owned by company insiders.

About AbbVie

(Free Report)

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.

Read More

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.